Infliximab
Colitis
Therakos LLCmonoclonal_antibodyPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Colitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vedolizumab Therakos LLC | Phase 2 | B |
Adalimumab National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
VITPSO Therakos LLC | Phase 2 | CCC |
Mesalamine National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
MERCAPTOPURINE ANHYDROUS National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
View all 13 →
Same molecule, other indications
Infliximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →